• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2021 Norwegian Institute of Public Health (NIPH) Surgery for carpal tunnel syndrome: a health technology assessment
2021 NIHR Health Technology Assessment programme Universal late pregnancy ultrasound screening to predict adverse outcomes in nulliparous women: a systematic review and cost-effectiveness analysis
2021 Norwegian Institute of Public Health (NIPH) Evaluation of tests for FLT3 mutations in acute myeloid leukaemia (AML)
2021 Norwegian Institute of Public Health (NIPH) Subacromial decompression surgery for impingement syndrome: rapid health technology assessment
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating pharmacological treatment for clearing an occluded central venous access device (CVAD)]
2021 Norwegian Institute of Public Health (NIPH) [Intravenous immunoglobulin treatment in children with PANS/PANDAS conditions]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: Hemlibra (emicizumab) – Hemophilia A without inhibitor (re evaluation)]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Lyme disease and persistent symptoms: a look at the current knowledge and recommendations for improving management]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: clinical utility of the different Western blot antigen profiles in the context of disseminated Lyme disease]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: chronic” Lyme disease: current state of knowledge and overview of the different perspectives]
2021 NIHR Health Technology Assessment programme Prognostic tools for identification of high risk in people with Crohn’s disease: systematic review and cost-effectiveness study
2021 Scottish Medicines Consortium (SMC) Afamelanotide (Scenesse) for prevention of photoxicity in adult patients with erythropoietic protoporphyria (EPP)
2021 Scottish Medicines Consortium (SMC) Upadacitinib for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)
2021 Scottish Medicines Consortium (SMC) Ravulizumab for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH): in patients with haemolysis with clinical symptom(s) indicative of high disease activity; in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months
2021 Scottish Medicines Consortium (SMC) Ozanimod for adult patients with relapsing remitting multiple sclerosis
2021 Scottish Medicines Consortium (SMC) Entrectinib as monotherapy for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion: who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity; and who have not received a prior NTRK inhibitor; who have no satisfactory treatment options
2021 Scottish Medicines Consortium (SMC) Onasemnogene abeparvovec treatment of patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA type 1, or patients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: validation of the management framework for a nonspecific human immunoglobulin shortage]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: standards for the management of acute ST-segment elevation myocardial infarction (STEMI) in Québec (update of April 2021)]
2021 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Internet-based psychological treatment for anxiety and depression]
2021 Scottish Health Technologies Group (SHTG) NHSScotland COPD Support Service: remote and self-management of high-risk patients with COPD using a web app and machine learning predictive modelling
2021 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Diagnostics and treatment of provoked vestibulodynia]
2021 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Continuity of care]
2021 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Lipoedema – diagnosis, treatment, and experiences]
2021 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Multimodal and interdisciplinary interventions for long term pain]
2021 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Caesarean section on maternal request]
2021 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatment and rehabilitation of people with fibromyalgia]
2021 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Programs for preventing suicide and suicide attempt in children]
2021 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Newborn screening for classic congenital adrenal hyperplasia. Update and assessment of regional programs]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Report: optimal use of immunoglobulins in rheumatology. Report in support of the optimal use guide English summary]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: efficacy and safety of immunoglobulins in rheumatology. Systematic review report]
2021 Austrian Institute for Health Technology Assessment (AIHTA) Robotics and functional electrical stimulation for stroke rehabilitation: systematic review
2021 Austrian Institute for Health Technology Assessment (AIHTA) [Parent-Child-Pass Update 2020/21 – Screenings for mental health, nutrition and social competence]
2021 Penn Medicine Center for Evidence-based Practice (CEP) Ambulatory blood glucose checks
2021 Penn Medicine Center for Evidence-based Practice (CEP) Prevention of opioid-induced respiratory depression (OIRD) in hospital care
2021 Penn Medicine Center for Evidence-based Practice (CEP) Fall prevention in ambulatory care facilities
2021 Penn Medicine Center for Evidence-based Practice (CEP) Triaging COVID-19 in the emergency department
2021 Penn Medicine Center for Evidence-based Practice (CEP) Critical value thresholds
2021 Norwegian Institute of Public Health (NIPH) Minimally invasive glaucoma surgery (MIGS) for individuals with glaucoma. A health technology assessment
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating diagnostic measures in a person with signs and symptoms suggestive of a urinary tract infection (cystitis or pyelonephritis) and initiating first-line pharmacological treatment for cystitis in an adult with functional autonomy decline]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: urinary catheter placement in an adult with functional autonomy decline presenting with symptoms suggestive of acute urinary retention]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating blood work for the purpose of evaluating diagnosed or suspected alcohol use disorder]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: initiating pharmacotherapy for relapse prevention in a person with alcohol use disorder]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: efficacy and safety of pharmacological treatments for alcohol withdrawal and relapse prevention]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: administration of benzodiazepines or gabapentin prescribed via an individual prescription for alcohol withdrawal]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: assessment and risk management of severe neurological complications following mild traumatic brain injury]
2021 European Network for Health Technology Assessment (EUnetHTA) Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia
2021 European Network for Health Technology Assessment (EUnetHTA) Convalescent plasma therapy for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Tocilizumab for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Camostat for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Nafamostat for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Solnatide for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Anakinra for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) APN01 for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Darunavir for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Favipiravir for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Sarilumab for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Interferon (IFN) and Novaferon (NOVA) for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Gimsilumab for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Canakinumab for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Casirivimab and imdevimab (REGN-COV2) for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Bamlanivimab for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Baricitinib for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Molnupiravir for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) High-dose vitamin D for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Mavrilimumab for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Ivermectin for the treatment of COVID-19
2021 European Network for Health Technology Assessment (EUnetHTA) Aspirin for the treatment of COVID-19
2021 Swiss Federal Office of Public Health (FOPH) Corneal collagen crosslinking for the treatment of progressive keratoconus
2021 Swiss Federal Office of Public Health (FOPH) Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis
2021 Swiss Federal Office of Public Health (FOPH) Medical cannabis for treating various symptoms in Switzerland
2021 Swiss Federal Office of Public Health (FOPH) Palbociclib (Ibrance®), ribociclib (Kisqali®) and abemaciclib (Verzenios®) for the treatment of hormone receptor (HR)-positive, human epidermal growth factor (HER2)-negative advanced breast cancer
2021 Swiss Federal Office of Public Health (FOPH) Subacromial decompression as a primary/isolated intervention to treat subacromial pain
2021 Swiss Federal Office of Public Health (FOPH) The treatment of hypercholesterolaemia and mixed/combined hyperlipidaemia with ezetimibe-containing medicines
2021 Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Screening for common mental disorders during pregnancy and for traumatic experiences after delivery]
2021 Norwegian Institute of Public Health (NIPH) [Liposuction (lipectomy) for the treatment of fat accumulation caused by chronic lymphoedema]
2021 Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: mandatory vaccination
2021 NIHR Health Services and Delivery Research programme Hospital-based specialist palliative care compared with usual care for adults with advanced illness and their caregivers: a systematic review
2021 Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: thrombotic adverse events with adenovirus vaccines
2021 NIHR Health Technology Assessment programme High-sensitivity troponin assays for early rule-out of acute myocardial infarction in people with acute chest pain: a systematic review and economic evaluation
2021 Norwegian Institute of Public Health (NIPH) [Natalizumab subcutaneous for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment - health economic evaluation]
2021 Norwegian Institute of Public Health (NIPH) [Ofatumumab for the treatment of relapsing remitting multiple sclerosis: a rapid health technology assessment – health economic evaluation]
2021 NIHR Health Technology Assessment programme Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users
2021 Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS) [Specific rehabilitation interventions for physical impairment to avoid chronification of non-specific back pain in adults]
2021 Penn Medicine Center for Evidence-based Practice (CEP) Opioids for vaso-occlusive crisis in pregnant patients
2021 Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: vaccination for women who are pregnant or lactating
2021 Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: management of vaccine-associated thrombotic syndromes
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: efficacy and safety of buprenorphine and methadone for the treatment of opioid use disorder]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: challenging behaviours - best practices in prevention, assessment and Intervention for people with an intellectual disability, physical disability or autism spectrum disorder]
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: oral opioid agonists for the treatment of opioid use disorder]
2021 Penn Medicine Center for Evidence-based Practice (CEP) COVID-19: effects of vaccines on fertility and pregnancy outcomes
2021 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: organization of care and services related to alternate levels of care (ALC)]
2021 Scottish Health Technologies Group (SHTG) Detection of paroxysmal atrial fibrillation in patients with newly diagnosed ischaemic stroke
2021 NIHR Health Technology Assessment programme Testing strategies for Lynch syndrome in people with endometrial cancer: systematic reviews and economic evaluation
2021 Health Technology Wales (HTW) Oscillating positive expiratory pressure devices for airway clearance in chronic hypersecretory lung conditions
2021 NIHR Health Technology Assessment programme Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review
2021 Norwegian Institute of Public Health (NIPH) [Hysterectomy for heavy menstrual bleeding: rapid health technology assessment]
2021 Andalusian Health Technology Assessment Area (AETSA) [18F-FDG in myocardial viability for revascularization]
2021 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula]
2021 Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Recommendations for the appropriate use of vitamin D tests and supplements in the general population]